Patients ( N = 1013 ) were randomized 2:2:2:1 to treatment with placebo , LY40 mg twice daily ( BID ) , LY80 mg BID , or risperidone ( RIS ) 2mg BID for 6weeks after a one-week blinded placebo lead-in .